Knowledge Hub · Europrobe™ Gamma Detection
Sentinel-node biopsy with intraoperative gamma-probe guidance is the standard of care across breast cancer (NSABP B-32), intermediate-thickness melanoma (MSLT-I / MSLT-II), early-stage vulvar cancer (GROINSS-V) and endometrial cancer (SENTI-ENDO). This page is the published evidence behind the technique, the NEMA NU3-2004 probe characterisation framework, and the CdTe vs CsI(Tl) energy-coverage trade-off that drives platform choice.
Why this matters
Sentinel-node biopsy as standard of care
The NSABP B-32 randomised trial (5611 patients) and the ALMANAC trial established that sentinel lymph node biopsy with gamma-probe guidance delivers equivalent locoregional control to axillary lymph node dissection (ALND) in clinically node-negative breast cancer — with substantially lower morbidity (lymphoedema, arm dysfunction, sensory loss). The Z0011 trial extended the principle to limited (1–2) positive SLNs in selected patients. The gamma probe is the workhorse of the SLN procedure; without it, the technique is not possible.
Melanoma — Morton & MSLT-I / MSLT-II
Donald Morton's original lymphatic mapping work and the subsequent MSLT-I trial (1347 patients) established SLN biopsy with gamma-probe guidance as the staging procedure for intermediate-thickness (1.2–3.5 mm) melanoma. MSLT-II then showed that completion lymphadenectomy after a positive SLN does not improve melanoma-specific survival — sharpening the SLN result's role as the dominant prognostic variable. Across both trials the gamma probe was the localisation tool; the surgical technique is built around it.
Gynaecological cancer SLN — cervix, endometrium, vulva
For vulvar cancer the GROINSS-V trial established SLN biopsy as the standard nodal procedure in selected patients, halving groin-recurrence morbidity vs full inguinofemoral lymphadenectomy. The SLN-FOX (Ouldamer et al.) and SENTI-ENDO (Ballester et al.) studies validated the technique in endometrial cancer with detection rates of 88–97 % using Tc-99m colloid + blue dye. The laparoscopic / robotic SLN probe geometry — frontal, lateral and 45° — is the OR-side requirement that makes the gynaecological workflow practical.
CdTe vs CsI(Tl) — energy coverage
CdTe (cadmium telluride) is the high-sensitivity choice at the Tc-99m (140 keV) workhorse range and at the I-125 (27 keV) low-energy range used for radio-guided occult-lesion localisation (ROLL). CsI(Tl) (caesium iodide, thallium-doped) extends the platform to I-131 (364 keV) for thyroid-remnant surgery and F-18 (511 keV with collimator) for selected PET-guided cases. A hospital running both breast-SLN and thyroid-remnant lists from the same OR can run both off the same console — the multi-platform cost goes away.
Probe characterisation under NEMA NU3-2004
NEMA NU3-2004 defines the standardised characterisation protocol for surgical gamma probes — sensitivity (cps per MBq at a fixed source distance), spatial resolution (FWHM), shielding (count drop-off at a fixed off-axis angle) and energy resolution. The published numbers translate directly to OR behaviour: higher sensitivity = faster localisation at faint / deep nodes; tighter spatial resolution = better discrimination against the injection-site hot spot; better shielding = lower false-positive count from adjacent activity in the surgical field. NEMA-compliant numbers are how one probe family is honestly compared to another.
Source: NEMA NU3-2004; Heller & Zanzonico Eur J Nucl Med 2011; Tiourina Eur J Nucl Med 2010.
AERB framework — pre-operative isotope handling
AERB Safety Code for Nuclear Medicine Facility governs the pre-operative isotope injection (typically Tc-99m-nanocolloid or Tc-99m-tilmanocept on the morning of surgery) including the dose-handling, transport and theatre-handling chain. The surgical team uses the probe; the nuclear-medicine team manages the radioisotope licence, the injection dose and the post-operative specimen-disposal log. Joint SOPs between the two departments are the practical foundation of a sustainable SLN programme.
Source: AERB Safety Code for Nuclear Medicine Facility; AERB radioactive-material licensing framework.
The clinical trials, the NEMA characterisation framework and the AERB regulatory base anchoring intraoperative gamma-probe practice in India.
Krag et al., Lancet Oncology 2010 — randomised trial establishing SLN biopsy as standard of care in clinically node-negative breast cancer (5611 patients).
Morton et al., NEJM 2014 — sentinel-node biopsy as the staging procedure of choice in intermediate-thickness melanoma.
Faries et al., NEJM 2017 — completion lymphadenectomy does not improve melanoma-specific survival after positive SLN.
Van der Zee et al., JCO 2008 — sentinel-node procedure as standard of care in selected early-stage vulvar cancer.
Ballester et al., Lancet Oncology 2011 — prospective multicentre evaluation of SLN biopsy in early-stage endometrial cancer.
NEMA standard defining the characterisation protocol (sensitivity, spatial resolution, shielding, energy resolution) by which surgical gamma probes are compared.
IAEA educational reference covering gamma-probe physics, characterisation and intraoperative use.
Open-access characterisation study (PMC7981324) of a modern gamma probe under the NEMA NU3-2004 protocol — useful baseline for interpreting published probe specs.
Indian regulatory framework — pre-operative SLN injection authorisation, theatre handling, specimen disposal.
Educational demonstrations of intraoperative gamma-probe SLN technique — open and laparoscopic approaches.